Zenocutuzumab-Zbco: uses, dosing, side effects & brands
Zenocutuzumab-Zbco is a medicine sold in the U.S. under one brand, for lung neoplasms and small cell lung carcinoma. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Lung Neoplasms and Small Cell Lung Carcinoma
- Available as
- Injectable
- Sold as
- Bizengri
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
- Boxed warning
- Boxed warning
How zenocutuzumab-zbco is dosed
From the FDA label for Bizengri (application BLA761352). Other zenocutuzumab-zbco products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Select patients for treatment with BIZENGRI based on the presence of an NRG1 gene fusion. ( 2.1 ) Evaluate left ventricular ejection fraction (LVEF) before initiating BIZENGRI. ( 2.2 ) The recommended dosage of BIZENGRI is 750 mg every 2 weeks until disease progression or unacceptable toxicity. ( 2.3 ) Administer premedications before each infusion to reduce the risk of infusion-related reactions. ( 2.4 ) Administer as an intravenous infusion, after dilution, over 4 hours. ( 2.7 ) 2.1 Patient Selection Select patients for treatment with BIZENGRI based on the presence of an NRG1 gene fusion in tumor specimens [see Clinical Studies (14.1 , 14.2 , 14.3) ] . An FDA-approved test for the detection of NRG1 gene fusions is not currently available. 2.2 Recommended Evaluation Before Initiating BIZENGRI Before initiating BIZENGRI, evaluate left ventricular ejection fraction (LVEF) [see Warnings and Precautions (5.3) ]. 2.3 Recommended Dosage The recommended dosage of BIZENGRI is 750 mg as an intravenous (IV) infusion every 2 weeks until disease progression or unacceptable toxicity [see Dosage and Administration (2.7) ]. Administer premedications before each BIZENGRI infusion as recommended to reduce the risk of infusion-related reactions [see Dosage and Administration (2.4) ] . 2.4 Recommended Premedications Prior to each infusion of BIZENGRI, administer premedications to reduce the…
Zenocutuzumab-Zbco side effects
The following clinically significant adverse reactions are described elsewhere in the labeling: Infusion-Related Reactions/Hypersensitivity/Anaphylaxis [ see Warnings and Precautions (5.1) ] Interstitial Lung Disease/Pneumonitis [see Warnings and Precautions (5.2) ] Left Ventricular Dysfunction [ see Warnings and Precautions (5.3) ] Embryo-Fetal Toxicity [ see Warnings and Precautions (5.4) ] The most common adverse reactions (≥ 10%) in patients were diarrhea musculoskeletal pain, fatigue, nausea, infusion-related reactions (IRR), dyspnea, rash, constipation, vomiting, abdominal pain, and edema. ( 6.1 ) The most common Grade 3 or 4 laboratory abnormalities (≥ 2%) were increased GGT, decreased hemoglobin, decreased sodium, decreased platelets, increased AST, increased ALT, increased alkaline phosphatase, decreased magnesium, decreased phosphate, increased aPTT and increased bilirubin. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Partner Therapeutics, Inc. at 1-888-479-5385 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety population described in the WARNINGS…
Who shouldn’t take zenocutuzumab-zbco
None. None. ( 4 )
Every zenocutuzumab-zbco product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Bizengri.
Related calculators
Frequently asked questions
What is zenocutuzumab-zbco?
Bizengri (Zenocutuzumab-Zbco) is a medication used to treat Lung Neoplasms, Small Cell Lung Carcinoma.
Can you take zenocutuzumab-zbco with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run zenocutuzumab-zbco against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does zenocutuzumab-zbco come in?
Across the brands we track, zenocutuzumab-zbco is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic zenocutuzumab-zbco?
We do not currently list a generic-labelled zenocutuzumab-zbco product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Zenocutuzumab-Zbco: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/zenocutuzumab-zbco
- MLA
- “Zenocutuzumab-Zbco: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/zenocutuzumab-zbco.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for zenocutuzumab-zbco on DailyMed (NIH) ↗ — including its boxed warning in full.